Relay Therapeutics (RLAY) Operating Leases (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Operating Leases data on file, last reported at $27.7 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $27.7 million, down 32.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.7 million (down 32.87% YoY), and the FY2025 annual result was $28.7 million, down 32.92% from the prior year.
• Operating Leases eased to $27.7 million in Q1 2026 per RLAY's latest filing, from $28.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $54.6 million in Q3 2022 and troughed at $20.0 million in Q2 2022.
• A 5-year average of $40.5 million and a median of $44.3 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2025: Operating Leases jumped 155.25% in 2023, then plunged 33.01% in 2025.
• A 5-year view of Operating Leases shows it stood at $53.5 million in 2022, then declined by 9.28% to $48.5 million in 2023, then decreased by 11.81% to $42.8 million in 2024, then tumbled by 32.92% to $28.7 million in 2025, then retreated by 3.53% to $27.7 million in 2026.
• Business Quant data shows RLAY's Operating Leases at $27.7 million in Q1 2026, $28.7 million in Q4 2025, and $29.7 million in Q3 2025.